Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

BACKGROUND. The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Reardon, David A., Lassman, Andrew B., van den Bent, Martin, Kumthekar, Priya, Merrell, Ryan, Scott, Andrew M., Fichtel, Lisa, Sulman, Erik P., Gomez, Erica, Fischer, JuDee, Lee, Ho-Jin, Munasinghe, Wijith, Xiong, Hao, Mandich, Helen, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle D., Gan, Hui K.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570193/
https://ncbi.nlm.nih.gov/pubmed/28039367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now257
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados